Stockscreener 앱 받기
27.84
0.83%
0.23
시간 외 거래:
27.61
-0.23
-0.83%
Moderna Inc 주식(MRNA)의 최신 뉴스
On the Move: Moderna's Cronin Moves to Medtronic Diabetes - O'Dwyer's PR
Ex-Moderna brand chief Kate Cronin joins Medtronic Diabetes as marketing lead - Medical Marketing and Media
Moderna, Inc. (NASDAQ:MRNA) Shares Sold by PDT Partners LLC - MarketBeat
Northern Trust Corp Purchases 354,871 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Moderna, Inc. (NASDAQ:MRNA) Shares Sold by Kovitz Investment Group Partners LLC - MarketBeat
Lido Advisors LLC Boosts Stock Holdings in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
The Manufacturers Life Insurance Company Acquires 267,990 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Moderna Stock Crumbles As Vaccine Troubles Rattle Its Topline - MSN
Moderna, Inc. (NASDAQ:MRNA) Shares Sold by Pinebridge Investments L.P. - MarketBeat
Moderna Q1 Earnings Ahead: Analysts expect loss amid increased regulatory scrutiny - MSN
Public Employees Retirement Association of Colorado Has $1.40 Million Stock Position in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Price T Rowe Associates Inc. MD Cuts Holdings in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Dimensional Fund Advisors LP Has $69.34 Million Position in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Moderna, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information – MRNA - ACCESS Newswire
Envestnet Asset Management Inc. Trims Stock Position in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Moderna, Inc. (NASDAQ:MRNA) Shares Sold by Aquatic Capital Management LLC - MarketBeat
UBS Analyst Lowers Price Target for MRNA, Maintains Buy Rating | - GuruFocus
XTX Topco Ltd Decreases Stock Position in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Barclays Lowers Price Target on Moderna (MRNA) to $40.00 | MRNA Stock News - GuruFocus
Moderna Pivots To Increase Focus On Cancer Amid US Vaccine Policy Changes - insights.citeline.com
Susquehanna Fundamental Investments LLC Invests $16.04 Million in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Moderna (MRNA) Price Target Lowered by RBC Capital | MRNA Stock News - GuruFocus
Moderna (MRNA) Target Price Cut by RBC Capital Amid Financial Up - GuruFocus
Moderna (NasdaqGS:MRNA) Reports Decrease in Q1 Revenue and Net Loss - Yahoo Finance
Moderna faces long-term threat from NIH’s universal vaccine initiative, Jefferies says - Proactive Investors
Moderna (MRNA) Downgraded as Financial Strains Emerge - GuruFocus
UBS Adjusts Price Target on Moderna to $70 From $78, Maintains Buy Rating - marketscreener.com
Moderna (MRNA) Analyst Maintains Rating but Lowers Price Target - GuruFocus
UBS Revises Price Target for Moderna (MRNA) Due to Vaccine Uncer - GuruFocus
Moderna (MRNA) Reports Q1 Earnings: What Key Metrics Have to Say - Yahoo Finance
Moderna Earnings Top Estimates. Why the Stock Is Dropping. - Barron's
Moderna price target lowered to $28 from $32 at RBC Capital - TipRanks
Moderna, Inc. (NASDAQ:MRNA) Q1 2025 Earnings Call Transcript - Insider Monkey
Berenberg holds Moderna stock with $30 target amid cost cuts - Investing.com
Berenberg holds Moderna stock with $30 target amid cost cuts By Investing.com - Investing.com UK
State of Tennessee Department of Treasury Sells 27,726 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Moderna Inc (MRNA) Q1 2025 Earnings Call Highlights: Navigating Challenges with Strategic Cost ... - Yahoo Finance
Moderna Inc (MRNA) Q1 2025 Earnings Call Highlights: Navigating - GuruFocus
Press Release Distribution & PR Platform - ACCESS Newswire
Moderna’s Q1 2025: Revenue Decline and Strategic Focus - TipRanks
Moderna Punts On US Vaccine Policy Changes, Will Focus More On Cancer - insights.citeline.com
Moderna shares fall on vaccine sales miss, delay in FDA review - The Boston Globe
Moderna combination flu, COVID shot delayed amid FDA scrutiny - BioPharma Dive
Moderna (MRNA) Price Target Cut by Citi Analyst Amid Concerns | - GuruFocus
Moderna (MRNA) Price Target Cut by RBC Capital Following Earnings Report | MRNA Stock News - GuruFocus
Moderna Cuts Costs as COVID Sales Slump - Yahoo Finance
Citigroup Cuts Moderna Price Target to $32 From $40 - marketscreener.com
Moderna, facing revenue misses and political headwinds, disappoints Wall Street - Endpoints News
Moderna: Regulatory Hurdles And Market Challenges Prompt Downgrade To Sell (NASDAQ:MRNA) - Seeking Alpha
Moderna Expands Cost-Cutting Program By Up To $1.7 Billion, FDA Approval For Flu/COVID-19 Combo Shot Delayed Into 2026 - Benzinga
Moderna says FDA has been constructive, but delays flu/COVID shot - Reuters
Moderna's Revenue Surpasses Expectations Despite First-Quarter Loss - Finimize
Moderna outlines $1.4B-$1.7B cost reductions by 2027 while advancing oncology pipeline - MSN
Moderna Reports Q1 Revenue Drop, Warns Of Delay In Covid/Flu Vaccine Approval: Retail Sentiment Sours - Investing.com India
Moderna First-Quarter Loss Unexpectedly Improves Even as Revenue Drops - marketscreener.com
0.39%
3.66%
자본화:
|
볼륨(24시간):